Larimar Therapeutics, Inc. LRMR
2.69 USD +0.16 (+6.32%)
At closeNov 10, 2026, 7:58 PM EST
2.69 0.00 +0.04%
After hours · Nov 10, 7:58 PM ET
2.46 Day range 2.74
1.92 52-week range 6.42
- YTD
- -29.40%
- 1 year
- -24.23%
News
benzinga.com Larimar Therapeutics Completes Rolling BLA Submission To FDA Seeking Accelerated Approval Of Nomlabofusp For Treatment Of Patients With Friedreich’s Ataxia Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA Submission follows FDA alignment on…
globenewswire.com Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich's Ataxia Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA Submission follows FDA alignment on…
globenewswire.com Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research BALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare…
globenewswire.com Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare…
marketbeat.com 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead Small-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading…
zacks.com Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for Larimar (LRMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts…
benzinga.com Larimar Therapeutics Appoints John Harlow As President and COO, Effective September 29 Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow…
globenewswire.com Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare…
zacks.com 5 Small Drug Stocks Poised to Benefit From a Biotech Recovery INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
defenseworld.net BlackRock Inc. Buys New Position in Larimar Therapeutics, Inc. $LRMR BlackRock Inc. purchased a new stake in Larimar Therapeutics, Inc. (NASDAQ: LRMR) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange…
defenseworld.net Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages Shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) have earned a consensus recommendation of "Buy" from the ten research firms that are currently covering the company,…
defenseworld.net Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR Dimensional Fund Advisors LP lifted its position in shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR) by 143.8% during the first quarter, according to the company in its most recent filing with the…
benzinga.com Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11 Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $12 to $11.
benzinga.com Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 26.83 percent increase over losses…
globenewswire.com Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update BALA CYNWYD, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such investors are…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such investors are…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such investors are…- benzinga.com HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10 HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ:LRMR) with a Buy rating and announces Price Target of $10.
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK, July 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are…
benzinga.com Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $5 Baird analyst Joel Beatty maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $7 to $5.
seekingalpha.com Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia Transcript Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia Transcript
benzinga.com Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug Larimar Therapeutics Inc (LRMR) submits first module of Biologics License Application for investigational treatment for Friedreich's ataxia, with FDA support and positive long-term data showing…
benzinga.com Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrollment of first patient in phase 3 trial.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday's pre-market session. The company's market cap stands at $1.9 million. Decoy Therapeutics…
benzinga.com Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announcing acquisition of Best Praise International for $10.75 million.- benzinga.com Larimar Therapeutics Submits First Module Of Rolling BLA Submission To FDA For Accelerated Approval Of Nomlabofusp; Remaining Modules Expected To Be Submitted In H2 2026 FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling BLA submitted with remaining modules expected 2H 2026 Daily nomlabofusp…
globenewswire.com Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich's Ataxia BALA CYNWYD, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare…
benzinga.com JP Morgan Initiates Coverage On Larimar Therapeutics with Overweight Rating, Announces Price Target of $9 JP Morgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Overweight rating and announces Price Target of $9.
benzinga.com Nvidia To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Monday Top analysts changed outlook on top names. Keybanc, Leerink, Wedbush, DA Davidson, Benchmark, Piper Sandler, Morgan Stanley, Evercore raised price targets.- benzinga.com Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $12 Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $13 to $12.
- benzinga.com Larimar Therapeutics Q1 EPS $(0.31) Beats $(0.54) Estimate Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.54) by 42.59 percent. This is a 32.61 percent increase over losses…
- benzinga.com Wedbush Maintains Outperform on Larimar Therapeutics, Raises Price Target to $13 Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and raises the price target from $12 to $13.
benzinga.com Earnings Scheduled For March 19, 2026 - benzinga.com Larimar Therapeutics Q4 EPS $(0.73) Misses $(0.45) Estimate Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.45) by 62.22 percent. This is a 62.22 percent decrease over losses…
benzinga.com Wedbush Maintains Outperform on Larimar Therapeutics, Raises Price Target to $12 Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and raises the price target from $11 to $12.
benzinga.com C3.ai Posts Downbeat Results, Joins Trade Desk, FTAI Aviation And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com Why Marriott Vacations Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - benzinga.com Larimar Therapeutics Commences $75M Common Stock Offering Larimar Therapeutics, Inc. ("Larimar") (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an…
benzinga.com Laminar Therapeutics Stock Is Popping Today: What's Going On? Larimar Therapeutics Inc (NASDAQ:LRMR) shares are soaring on Wednesday after multiple analysts reiterated their bullish outlook.- benzinga.com Citigroup Maintains Buy on Larimar Therapeutics, Raises Price Target to $14 Citigroup analyst Samantha Semenkow maintains Larimar Therapeutics (NASDAQ:LRMR) with a Buy and raises the price target from $12 to $14.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Acadia Healthcare Posts Upbeat Q4 Earnings, Joins Circle Internet, Resideo Technologies And Other Big Stocks Moving Higher On Wednesday - benzinga.com Wedbush Reiterates Outperform on Larimar Therapeutics, Maintains $11 Price Target Wedbush analyst Laura Chico reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and maintains $11 price target.
benzinga.com Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views 
benzinga.com Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation Larimar Therapeutics Inc (NASDAQ: LRMR) shares are trading sharply higher Tuesday after the company said the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session